Extracellular genomic biomarkers of osteoarthritis by Budd, Emma et al.
  1 
Extracellular Genomic Biomarkers of Osteoarthritis 
Emma Budd a, b, Giovanna Nalesso b, Ali Mobasheri a, b, c 
 
a The D-BOARD European Consortium for Biomarker Discovery, School of Veterinary Medicine, 
Guildford, University of Surrey, GU2 7XH, United Kingdom 
b Department of Veterinary Pre-Clinical Sciences, School of Veterinary Medicine, Faculty of Health 
and Medical Sciences, University of Surrey, Guildford, GU2 7XH, United Kingdom 
c Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Queen’s Medical Centre, 
Nottingham, NG7 2UH, United Kingdom 
 
* Address correspondence and reprint requests to: Dr Emma Budd, School of Veterinary Medicine, 
University of Surrey, Guildford, GU2 7AL, United Kingdom 
 
E-mail addresses: 
e.budd@surrey.ac.uk (Emma Budd) 
g.nalesso@surrey.ac.uk (Giovanna Nalesso) 
a.mobasheri@surrey.ac.uk (Ali Mobasheri) 
 
Authors' contributions: E.B. conceived, drafted and edited the manuscript. G.N. edited and approved 
the submission. A.M. edited and approved the submission. All authors contributed to data interpretation 
and manuscript preparation and approved the final version submitted. 
 
Acknowledgements: The research leading to these results was funded by the European Commission 
Framework 7 programme (EU FP7; HEALTH.2012.2.4.5-2, project number 305815; Novel Diagnostics 
and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases). This project has also 
received partial support from the Innovative Medicines Initiative Joint Undertaking under grant 
agreement No. 115770, resources of which are composed of financial contribution from the European 
Union’s Seventh Framework programme (FP7/2007-2013) and EFPIA companies’ in-kind 
contribution. The funders had no role in study design, data collection and analysis, decision to publish, 
or preparation of the manuscript. 
  2 
 
Disclosure statement: The authors declare that they have no competing interests. This paper was 
written by the authors within the scope of their academic and research positions. None of the authors 
have any relationships that could be construed as biased or inappropriate. A. Mobasheri is coordinator 
of the D-BOARD Consortium funded by the European Commission Framework 7 programme (EU FP7; 
HEALTH.2012.2.4.5-2, project number 305815; Novel Diagnostics and Biomarkers for Early 
Identification of Chronic Inflammatory Joint Diseases) and member of the Arthritis Research UK 
Centre for Sport, Exercise, and Osteoarthritis, funded by Arthritis Research UK (grant reference 
numbers: 20194 and 21595). A.M. is a member of the Applied Public-Private Research enabling 
OsteoArthritis Clinical Headway (APPROACH) consortium, a 5-year project funded by the European 
Commission’s Innovative Medicines Initiative. APPROACH is a public-private partnership directed 
towards osteoarthritis biomarker development through the establishment of a heavily phenotyped and 
comprehensively analysed longitudinal cohort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  3 
Abstract 
 
Introduction 
Osteoarthritis (OA), a chronic, debilitating and degenerative disease of the joints, is the most common 
form of arthritis. The seriousness of this prevalent and chronic disease is often overlooked. Disease 
modifying OA drug (DMOAD) development is hindered by the lack of soluble biomarkers to detect 
OA early. The objective of OA biomarker research is to identify early OA prior to the appearance of 
radiographic signs and the development of pain.  
Areas covered 
This review has focused on extracellular genomic material that could serve as biomarkers of OA. Recent 
studies have examined the expression of extracellular genomic material such as miRNA, lncRNA, 
snoRNA, mRNA and cell-free DNA (cfDNA), which are aberrantly expressed in the body fluids of OA 
patients. Changes in genomic content of peripheral blood mononuclear cells (PBMCs) in OA could also 
function as biomarkers of OA.  
Expert commentary 
There is an unmet need for soluble biomarkers for detecting and then monitoring OA disease 
progression. Extracellular genomic material research may also reveal more about the underlying 
pathophysiology of OA. Minimally-invasive liquid biopsies such as synovial fluid and blood sampling 
of genomic material may be more sensitive over radiography in the detection, diagnosis and monitoring 
of OA in the future. 
Key words 
Osteoarthritis; Extracellular; Genomic biomarkers; Body fluids; Liquid biopsy; ncRNA; miRNA; 
cfDNA; mRNA; extracellular nucleic acid carriers 
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1. The current perspective on osteoarthritis 
Osteoarthritis (OA) is a chronic and debilitating disease of the joints which is more prevalent than 
rheumatoid arthritis (RA) and any other arthritic disease [1]. Osteoarthritis (OA) is characterised by 
progressive deterioration of hyaline cartilage concomitant with changes in surrounding tissues including 
ligaments, synovium and subchondral bone, resulting in defective integrity of affected articular joints 
or the spine [2]. OA is classified as a low-grade yet chronic inflammatory disease, with inflammation 
having a role in many of the associated pathologic changes [3]. Articular cartilage is alymphatic, aneural 
and avascular, with non-proliferative and non-migratory resident chondrocytes, factors which are likely 
to contribute the development of OA in part due to the limited capacity that articular cartilage has for 
endogenous regeneration [4]. OA is a heterogeneous disease which can be driven by different 
underlying factors. Phenotypic subgroups include a traumatic injury driven phenotype, an ageing driven 
phenotype, a synovitis-inflammatory driven phenotype, a subchondral bone phenotype, a cartilage 
driven phenotype and a metabolic phenotype [1]. The most common risk factors for OA include prior 
joint injury, age, sex, genetic predisposition and mechanical factors such as malalignment [5].  
Not only is OA the most common form of arthritis [6], it is the most common disease of the joints [7]. 
It has been estimated that approximately 33% of the UK’s population aged over 45 have sought 
treatment for OA [8]. OA is part of a wider group of diseases which cumulatively are known as 
musculoskeletal conditions. In 2015 in the UK, musculoskeletal disorders remained to be the leading 
cause of years lived with disability and an estimated 30.8 million working days were lost in 2016 due 
to a musculoskeletal condition [8].  In 2013/14 musculoskeletal conditions were accountable for the 3rd 
largest area of national health care (NHS) programme spending, costing £4.7 billion [8]. With an ageing 
population and increasing life expectancy the burden of OA will only increase, which poses an unmet 
need for the development of new therapies, preventative measures and the identification of sensitive 
biomarkers for OA diagnosis. 
Despite OA being the most common form of arthritis, OA still remains to gain recognition as a serious 
disease. It has been reported that 78% of people living with arthritis agreed that society doesn’t 
understand their condition because it doesn’t appear as if their condition is serious [8]. In December 
2016 the Pre-competitive Consortium for Osteoarthritis (PCCOA) of the Osteoarthritis Research 
Society International (OARSI) submitted a white paper to the Food and Drug Administration (FDA) in 
order to attract the attention of the FDA and policy makers to understand the need for effective therapies 
for OA [9]. The submission of the white paper was as a result of OA experts to portray the seriousness 
of this chronic and prevalent disease, highlighting the economic burden of OA upon society and the 
detrimental effects of OA on quality of life, which may deny OA sufferers the right to healthy ageing 
and basic human rights which are outlined in the United Nations Charter for Rights of Persons with 
Disability [9].  The white paper was submitted to encourage the development of global and national 
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health policies to address the increasing burden of OA and encourage drug development towards 
identifying disease modifying osteoarthritis drugs (DMOADs). Drug and biomarker development are 
interdependent, therefore DMOAD development is dependent on sensitive biomarkers which can detect 
and predict disease progression [10]. 
2. Limitations in diagnosing osteoarthritis  
In an era where the use of biomarker analysis to confirm or assess disease state is rapidly advancing, 
OA lacks the use of any soluble biomarker for diagnosis in the clinical setting. To identify individuals 
with early-onset OA a screening method to detect biomarkers from body fluid could help in the early 
diagnosis, and in the future, utilised in companion with a therapy in the treatment of the disease. 
Radiographs and joint imaging techniques, which are currently routinely used for a diagnosis of OA, 
do not measure dynamic changes in the joint and are usually implemented when OA is symptomatic at 
which point OA has progressed to advanced stages of the disease [11]. Radiography is the most common 
imaging modality to assess OA, with the use of radiographic grading or scoring classification systems  
to classify stages of OA [12]. One of the most commonly used radiographic definitions of OA is the 
Kellgren and Lawrence (KL) classification which grades the whole joint with a score from 0 to 4, with 
grade 0 as no OA and grade 4 as severe OA. The KL classification is based on radiographic observation 
of joint space narrowing, marginal osteophytes, subchondral bone sclerosis and bone shape alteration 
[12]. While imaging techniques such as radiography can detect and monitor structural changes to the 
joint, giving an indication of disease stage, the rate of OA development and disease progression cannot 
be evaluated. Imaging techniques can classify OA by structural change only, a KL score of 0 may 
indicate no OA, but molecular changes at the cellular level may have occurred, for which there is no 
current method of detection. Joint imaging techniques can only assess structural change at which point 
OA development is irreversible. A requirement to define and detect the changes which occur during 
OA disease initiation is needed for which there is a  requirement for a sensitive biomarker that can 
detect and diagnose early-onset OA and monitor disease progression.  
A compounding limitation in OA diagnosis is the range in symptomology which accompanies the 
disease in different individuals. Asymptomatic OA is a common phenomenon in which disease 
progression continues with a lack of symptoms in some patients [13]. Knee pain, for example, can be a 
symptom of OA, but is an imprecise indicator for OA which may not be necessarily correlated with 
radiographic findings, likewise radiographic knee OA is an imprecise indicator that knee pain will be 
present. OA has been found to be absent in individuals following radiography despite knee pain 
suggestive of OA and OA has been found to be present through compounding radiographic evidence in 
individuals that are asymptomatic [14]. There is no defining risk profile which can predict if an 
individual has significant damage to cartilage, if an individual has asymptomatic OA, if an individual 
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will develop OA or what the progression of destruction to articular cartilage and the joint will be or the 
rate of OA progression [15].   
OA is often not diagnosed until late stages, after significant, destructive and irreparable damage to the 
joint has already occurred. It has been suggested that molecular indicators exist long before radiographic 
evidence indicates the presence of OA and it has been estimated that the OA process begins 20 years 
before OA is detected by radiographic joint space narrowing (JSN) [16]. The issue lies with the 
diagnosis of OA, clinically detectable OA is currently confirmed by magnetic resonance imaging 
(MRI), ultrasound, nuclear medicine bone scans and/or radiography, but currently there is no method 
to detect biomarkers from extracellular body fluids. Early-stage OA has been defined and involves 
structural changes to the cartilage [17]. Ryd et al have attempted to define a stage in the OA disease 
process prior to early-stage OA known as pre-OA. Pre-OA is defined as the preclinical stage in OA 
whereby OA has been established for a length of time at the cellular level only, prior to early-stage OA 
which is distinguished by changes in cartilage structure [18]. Ryd et al suggest that the definition of 
pre-OA should be: ‘A knee exhibiting one or many risk factors without pain, normal standing 
radiographs, no structural changes on arthroscopy or standard MRI, this is, before early OA can be 
diagnosed’ [18]. Preventative measures should be applied at the pre-OA stage to forestall the onset of 
OA, but first, this stage needs to be identified in individuals. 
When discussing the development of biomarkers, it is important to highlight that the identified 
biomarker/s will be anticipated to be utilised in screening for OA, therefore the method of how potential 
biomarkers are isolated from the body must be minimally invasive. Other than in arthroscopic 
debridement, articular cartilage biopsy is not advocated in the clinic to investigate disease status because 
articular cartilage does not regenerate. The evaluation of  extracellular body fluids including synovial 
fluid, blood, plasma, serum and urine are of interest in identifying a soluble OA biomarker due their 
relative ease in being isolated from the body [19]. 
In recent years much of OA biomarker research has focused on proteomic techniques [2]. The view 
exists that proteomic approaches are advantageous over nucleic acid expression profiling because there 
is not the potential disconnection that can occur between gene expression and protein expression levels 
[20] as a result of post-translational modification.  The secretome is comprised of secreted proteins  and 
reflects the health of cells in real time [21]. Recent attention has turned to utilising proteomic techniques 
to identify proteins in the secretome of articular cartilage models of OA, as a potential indicator of 
disease biomarkers which may be present in the synovial fluid or blood in OA [22].  Proteomic profiling 
has focused on body fluids from OA patients in the search for a biomarker which is inherent to OA [23-
32]. The perception exists that extracellular genomic material is unstable as a result of harsh 
extracellular environments which may have contributed to a lack of focus on the extracellular 
environment for OA genomic biomarker discovery. 
  7 
The International Conference on Harmonisation (ICH) Topic 15 defined a genomic biomarker as ‘A 
measurable DNA and/or RNA characteristic that is an indicator of normal biologic processes, 
pathogenic processes, and/or response to therapeutic or other interventions’ [33]. A genomic biomarker 
includes measurements of gene expression, gene function and regulation of a gene and can include 
DNA/RNA characteristics such as SNPs, haplotypes, variability of short sequence repeats, DNA 
modifications, copy number variations, deletions or insertions of (a) single nucleotide(s), cytogenetic 
rearrangements, RNA sequences, RNA processing, RNA expression levels and miRNA levels [33].  
Pre-OA which is asymptomatic, established at the cellular level and not accompanied by structural 
changes and therefore undetectable by radiography, requires a method of detection before structural 
changes ensue [34]. Extracellular genomic material originates from the intracellular environment and 
may be more informative than extracellular matrix proteins with regards to the intracellular changes 
which occur prior to the onset of structural changes in OA. Not only could genomics identify genomic 
biomarkers of OA but also reveal more about the underlying cellular pathophysiology.  
3. Emerging extracellular genomic biomarkers of osteoarthritis 
An extensive array of RNAs have been suggested to exist within extracellular spaces and analysis of 
sequencing data from plasma-derived RNA identified 1,192 human extracellular RNA including 
miRNAs, piRNAs and snRNAs [35]. Extracellular vesicles (EVs) have been found to contain DNA, 
mRNA and subsets of ncRNA [36].  Ubiquitous ribonucleases present in body fluids degrade 
extracellular RNA [37], but exosomal-derived RNA has been shown to remain stable following RNase 
A treatment [38].  Extracellular miRNA and potentially other classes of RNA may remain stable in 
extracellular nuclease-rich environments as a result of extracellular carriers such as exosomes, 
microvesicles, apoptotic bodies, lipoproteins or protein complexes [39]. In addition to extracellular 
carrier-associated nucleic acids, cfDNA not associated with any carrier exists in the extracellular 
environment [40]. Table 1 lists and Figure 1 illustrates both extracellular carrier-associated and 
extracellular carrier-free genomic material which have the potential to serve as genomic biomarkers in 
OA.  
3.1 Functional non-coding RNA (ncRNA) in osteoarthritis 
The genome contains protein-coding DNA sequences that are transcribed to produce messenger RNA 
(mRNA) which in turn are translated to polypeptide sequences, and non-coding DNA, sequences some 
of which are transcribed to functional RNA sequences but are not translated into polypeptides (Figure 
2). 1-2% of the human genome encodes proteins [41], with the other 98-99% of the human genome 
comprising non-coding DNA. Important to note is the distinction between functional non-coding DNA, 
which includes DNA sequences for example cis-regulatory elements, scaffold/matrix (S/MAR) 
attachment regions, introns, telomeres and DNA which encodes genes for non-coding RNA, and, non-
functional non-coding DNA, which has no known function [42]. Regardless of the exact proportion of 
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functional non-coding genomic DNA, there exists a proportion which is transcribed into functional 
RNA (ncRNA) which includes small nuclear RNA (snRNA), transfer RNA (tRNA), ribosomal RNA 
(rRNA), small nucleolar RNA (snoRNA), microRNA (miRNA), piwi-interacting RNA (piRNA), 
circular RNA (circRNA) and long non-coding RNA (lncRNA) [43]. Definitions of functional ncRNA 
are described in Table 2. 
NcRNAs can be classified into two groups. NcRNAs that are constitutively expressed and have 
infrastructural or housekeeping functions, involved in translation, RNA splicing and DNA replication, 
include tRNA, rRNA and snRNA. While ncRNAs such as miRNA, piRNA and lncRNA which may 
haves roles in gene expression regulation, classified as regulatory ncRNAs, can themselves be 
differentially expressed [44]. Diseases have been attributed to perturbation in protein coding gene 
expression, focus has now turned to looking at the role that ncRNAs may have in disease. The 
expression of ncRNAs, like mRNA and protein, can be quantified which offers the potential to measure 
subsets of ncRNAs as indicators of disease state and therefore ncRNAs may serve as genomic 
biomarkers. Dysregulation of ncRNAs have been observed in tumorigenesis and in cardiovascular, 
autoimmune, monogenic, neurological, developmental and imprinting disorders [45]. Subsets of 
ncRNAs have been detected and remain stable in body fluids [46], thus circulating ncRNAs may qualify 
as potential biomarkers for OA. Discussed below are some of the ncRNAs that have been identified in 
extracellular fluids in OA. 
3.1.1 MicroRNA 
MicroRNA (miRNA) are single stranded ncRNA of approximately 22 nucleotides in length. MiRNA 
function by binding to locations within mRNA, typically within the 3’UTR, following RNA 
transcription [47]. The binding of miRNA to mRNA, in the cytoplasm, prevents mRNA translation in 
the synthesis of protein. MiRNA is therefore capable of down-regulating protein expression through 
effective mRNA targeting [48]. MiRNA research has focused on identification of intracellular miRNA, 
given that miRNA exert their function of down-regulating protein expression in the cell cytoplasm. 
Numerous studies have shown the differential expression of different miRNAs from OA cartilage; the 
expression of miR-140 [49], miR-125b [50], miR-210 [51], miR-222 [52], miR-199a* [53], miR-588 
[54], miR-411 [55], miR-105 [56], miR-502-5p [57] have been shown to be down-regulated in human 
OA chondrocytes and/or cartilage and the expression of miR-146b [4], miR-181b [58], miR-30a [59], 
miR-455 [60], miR-30b [61], miR-16-5p [62], miR-146a [4,63] have been shown to be up-regulated in 
human OA chondrocytes and/or cartilage. However, differential miRNA expression in cartilage-centric 
OA studies does not prove useful in identifying a non-invasive extracellular miRNA biomarker for 
diagnostic purposes. 
Weber at al identified miRNA in 12 body fluids, including breast milk, amniotic fluid, saliva, plasma, 
tears, urine cerebrospinal fluid, colostrum, seminal fluid, peritoneal fluid and pleural fluid [64]. Release 
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of miRNAs into cell culture media has been correlated with cell death and damage in specific tissues 
has been shown to result in an increase in the level of tissue specific miRNAs in circulation [65]. But, 
miRNA may be more than by-products of cell apoptosis or necrosis [66] and may also have a potential 
role in extracellular cell-cell communication [65]. Expression of stable extracellular miRNA could 
prove useful as a biomarker in OA. 
Synovial Fluid  
The concentration of miR-16, miR-146a, miR-155 and miR-223 were found to be significantly higher 
in synovial fluid from RA patients compared to the synovial fluid from knee OA patients [67]. An 
assessment of miR-16, miR-146a, miR-155 and miR-223 concentration could be diagnostic in 
discriminating knee OA from RA. MicroRNA profiling of non-OA and knee OA synovial fluid-derived 
EVs from males and females identified miR-504-3p as the only miRNA to be expressed in both genders, 
which indicates the potential need to examine miRNAs as biomarkers of OA by gender segregation 
[68]. Validation with qPCR of randomly selected miRNAs observed a significant down-regulation of 
miR-26a-5p, miR-146a-5p and miR-6821-3p in female knee OA synovial fluid-derived EVs, consistent 
with the miRNA microarray expression results [68], indicating the use of these microRNAs as 
diagnostic biomarkers in female knee OA. 
MicroRNA profiling and follow-up qPCR validation of synovial fluid from patients with early stage 
radiographic knee OA compared with the synovial fluid of patients with late stage radiographic knee 
OA revealed significant elevation of miR-23a-3p, miR-24-3p, miR-27a-3p, miR-27b-3p, miR29c-3p, 
miR-34a-5p, miR-186-5p and miR-378a-5p in late-stage OA [69]. An assessment of the expression of 
these miRNAs may therefore give an indication of OA progression. Treatment of synovial explants 
derived from patients with knee OA, with IL-1β, resulted in the significant up-regulation of miR-23a-
3p and miR-27b-3p, indicating that miR-23a-3p and miR-27b-3p could serve as biomarkers of 
inflammatory induced knee OA [69]. Similarly, miR-140 expression analysis was conducted on 
synovial fluid from patients that had radiographic mild, moderate and severe OA and compared to the 
synovial fluid of patients with no OA. Expression of miR-140 was found to be down-regulated with 
increasing radiographic severity of OA [70]. Expression of synovial fluid-derived extracellular miR-
140 could serve as a biomarker of OA progression.  
Components of blood 
The serum from individuals with OA-related knee and/or hip arthroplasty was compared to the serum 
from individuals without arthroplasty for miRNA expression. Let-7e was found to be significantly 
down-regulated in patients with OA-related knee and/or hip arthroplasty and was also found to be 
continuously decreased with increasing number of hip and/or joint replacement surgeries [71]. 
Expression of serum-derived Let-7e could serve as a biomarker for severe hip or knee OA.  
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Human TaqMan miRNA array and follow-up qPCR validation of total RNA from the plasma of patients 
with primary knee OA and patients without OA identified significant up-regulation of 10 miRNAs in 
OA plasma, including miR-16, miR-146a, miR-29c, miR-93, miR-126, miR-184, miR-186, miR-195, 
miR-345 and miR-885-5p [72], indicating their use as biomarkers of knee OA. Total RNA isolated from 
the plasma of patients with knee OA was compared to healthy controls. The expression of miR-19b-3p, 
miR-122-5p, miR-486-5p and miR-92a-3p were found to be significantly up-regulated in the plasma of 
OA patients. Univariate and multivariate logistic analysis identified miR-19-3p, miR-122-5p and miR-
486-5p to be independent factors for risk of knee OA. ROC curve analysis revealed that a combination 
of miR-19-3p, miR122-5p and miR-486-5p resulted in a high diagnostic value for knee OA, indicating 
that the combined measurement of all 3 extracellular miRNAs from plasma could serve as soluble 
genomic biomarkers for knee OA [73]. 
Another source of miRNA is from cells which reside within the peripheral blood. The expression of 
miR-146a, miR-155, miR-181a and miR-223 were found to be significantly up-regulated in peripheral 
blood mononuclear cells (PBMCs) from both, patients with knee OA and in patients with RA, compared 
to PBMCs from healthy controls. miR-146a, miR-155 and miR-223 were also observed to be 
significantly up-regulated in PBMCs from patients with RA compared to PBMCs from patients with 
knee OA [74]. An assessment of miR-146a, miR-155 and miR-223 expression from PBMCs could be 
diagnostic in discriminating knee OA from RA. Additional examination found that the expression of 
miR-155 was found to be significantly up-regulated in late-stage radiographic OA when compared to 
earlier radiographic stages of OA, whereas, expression of miR-146a and miR-223 were found to be 
significantly up-regulated in early-stage radiographic OA compared to late-stage radiographic OA [74]. 
Combined assessment of miR-146a, miR-155 and miR-223 expression levels from PBMCs could serve 
as diagnostic indicators of disease progression. 
3.1.2 Long non-coding RNA (lncRNA) 
Due to their diverse structures and functions the definition of lncRNAs is limited to ncRNAs of more 
than 200 nucleotides in length which lack protein coding capability [75]. Attempts have been made to 
classify lncRNAs by means of their relationship to coding genes, genomic origin and level of processing 
[76]. For example, lncRNAs have been classified according to molecular mechanism and can be 
subtyped as having signalling, decoy, guide, scaffold and enhancer roles [77]. LncRNAs can also be 
subtyped according to their position and direction of transcription relative to other genes and can be 
classified into subtypes including intergenic, intronic, antisense, overlapping, processed and bi-
directional lncRNAs [78].  
Zhang et al observed the expression of the lncRNA HOTAIR to be significantly up-regulated in the 
synovial fluid of the temporomandibular joint (TMJ) of OA patients and also in the synovial fluid of 
mechanical-stress-induced OA TMJ in rabbits. The authors demonstrated that treatment of rabbit TMJ 
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condylar chondrocytes with IL-1β induced the up-regulation of HOTAIR and knockdown of HOTAIR 
resulted in down-regulation of both mRNA and protein levels of Mmp1, Mmp3 and Mmp9 and a 
decrease in IL-1β induced apoptosis, indicating that the lncRNA HOTAIR may play a role in 
chondrocyte apoptosis in OA [79]. Synovial fluid HOTAIR from TMJs could potentially function as a 
biomarker of OA of the TMJ joint. 
The knowledge surrounding extracellular lncRNA expression in OA is limited, but studies of lncRNA 
expression in cells of the OA joint have been documented. Expression of lncRNAs in OA cartilage 
tissue and/or chondrocytes and synoviocytes, such as PCGEM1, GAS5, HOTTIP, LncRNA-CIR, H19, 
CILinc01 and CILinc02 have been observed, with roles in apoptosis, ECM degradation and 
inflammation [80]. Various studies have demonstrated expression of circulating lncRNAs in body fluids 
of cancer patients including in whole blood, urine, plasma, saliva and gastric juice [46] and circulating 
lncRNAs have been identified in endometriosis [81], acute myocardial infarction [82] and rheumatoid 
arthritis [83]. The field of lncRNA research is relatively young but holds promise for novel potential 
prognostic biomarkers for diseases including OA. It is likely that other extracellular lncRNAs involved 
in OA are yet to be identified. 
3.1.3 Small Nucleolar RNA (snoRNA) 
SnoRNAs, a sub-class of snRNA located in the nucleus, are involved with post-transcriptional 
modification by means of methylation or pseudouridylation of ncRNA including snRNA, rRNA and 
tRNA. SnoRNAs are divided into two classes, SNORDs and SNORAs, dependent on their structural 
features and sequences [84]. SnoRNAs are involved in rRNA processing, which is fundamental for 
ribosome biogenesis and ultimately translation and protein synthesis. Dysregulation of snoRNA is 
likely to have an impact on protein synthesis. Dysregulation of snoRNAs has been observed in certain 
cancers, neurodegenerative disease and viral induced diseases and changes in snoRNA levels have been 
observed in cells subjected to stress and drugs [85]. Differential expression of specific snoRNAs has 
also been observed in patients with cartilage damage associated with post-anterior cruciate ligament 
(ACL) damage [86] and in OA [87]. 
Zhang et al investigated the presence of ncRNA in the serum of patients with cartilage damage one year 
after patients had undergone arthroscopic ACL reconstruction surgery following ACL injury. The study 
looked to identify potential ncRNAs involved in early degenerative changes which may be associated 
with post-ACL injury-induced OA. At one year post-ACL injury, the concentration of U48 and U38 
were significantly elevated in the serum of patients developing cartilage damage. The concentration of 
U38 was also found to be significantly elevated in cartilage with greater damage, assessed by whole 
organ magnetic resonance knee score, compared to cartilage with minor damage. Not only could both 
U48 and U38 from serum serve as biomarkers of cartilage damage which may lead to OA, but 
assessment of U38 concentration could be utilised to discriminate between stages of cartilage damage 
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[86]. If U38 concentration is correlated with increasing cartilage damage it may be a good indicator for 
early-onset injury-induced OA, further examination of U38 in early radiographic OA would be 
insightful. 
In an in vivo experimental induced OA murine model, the expression of SNORD116, SNORA64 and 
U3 were found to be significantly up-regulated and the expression of SNORD46 was found to be 
significantly down-regulated in mice serum. The up-regulated expression of  SNORD116 was also 
confirmed in another species, with a significant up-regulation in SNORD116 observed in OA equine 
serum [87]. SNORA64, U3, SNORD46 and SNORD116 could serve as biomarkers of OA and future 
examination of the expression of these snoRNAs in human OA serum is required. 
3.2 Cell-Free, Carrier-Free Nucleic Acids  
Cell-free nucleic acids encompass DNA and RNA which are not associated with cells, freely circulating 
in the blood and other body fluids [88]. Apoptosis or necrosis has been speculated to be the main source 
of cfDNA and RNA in plasma and serum [89,90]. CfDNA is not carrier-associated, while cell-free RNA 
is likely to be associated with a carrier [40]. Extracellular cfDNA is double stranded and short in length 
due to fragmentation, with most DNA molecules measuring approximately 170 bp in length, resemblant 
of the smallest nucleosomal DNA fragment resultant of apoptosis [91]. Elevated cfDNA has been 
observed in various human diseases including myocardial infarction [92], acute pancreatitis [93], 
rheumatoid arthritis, systemic lupus erythematosus [94] and various types of cancer [95]. 
Leon et al examined the levels of extracellular DNA from patients with RA, OA, gout, pseudogout and 
post-traumatic arthritis (TRA) and identified that the concentration of DNA from both synovial fluid 
and serum was significantly higher in patients with RA compared to OA [96]. Hashimoto et al observed 
a significant increase in the concentration of cfDNA in the synovial fluid of RA patients compared to 
the concentration in OA patients [97]. Extracellular cfDNA may therefore serve as a biomarker to 
distinguish OA from RA. While DNA levels have been compared in RA and OA, no study has examined 
the levels of cfDNA in progressive radiographic OA. In late-stage OA chondrocyte apoptosis is 
evidenced by hypocellularity and lacunae emptying [98]. Given the association of increased cfDNA 
with elevated apoptosis or necrosis [99], an elevated level of cfDNA may be detected in late-stage 
radiographic OA compared to an earlier stage of radiographic OA. 
3.3 Peripheral blood mononuclear cells (PBMCs) as a source of genomic biomarkers 
Circulating blood contains PBMCs which encompass lymphocytes, natural killer cells, dendritic cells, 
monocytes [100] and a small percentage of haematopoietic stem and progenitor cells [101]. PBMCs are 
resident in an easily attainable fraction of blood, comprised of cells which actively undergo transcription 
and translation. The circulating mononuclear cells undergo immunophenotypic changes in response to 
disease and injury and therefore provide a peripheral source [102] for assessing gene and ncRNA 
expression relevant to different diseases. Chronic low-grade inflammation is a major driver of continual 
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degeneration of joint tissues in OA [103]. Infiltration of subsets of PBMCs including T and B 
lymphocytes, natural killer cells and macrophages into the synovium [103,104] and alterations in blood 
immune cell composition has been observed in OA [105]. Gene expression profiling of PBMCs offers 
a minimally invasive technique for potentially identifying novel biomarkers for OA.  
Several studies have identified specific gene expression profiles of PBMCs in OA, which could serve 
as novel genomic biomarkers of the disease. As discussed previously, the significant up-regulation of 
miR-146a, miR-155, miR-181a and miR-223 was observed in PBMCs isolated from patients with knee 
OA [74]. RNA expression profiling of RNA isolated from the blood of patients with arthroscopically 
diagnosed mild knee OA revealed 3,543 genes to be differentially expressed. Significant down-
regulation of HSPCA, IKBKAP, IL13RA1, LAMC1, TNFAIP6 and PF4 mRNA following qPCR 
validation was observed in patients with mild knee OA compared to controls [106]. Marshall et al 
suggest that utilising a combination of specific mRNA expression analysis of blood-derived RNA 
provides a more sensitive and non-invasive method to diagnose mild knee OA [106]. Ramos et al 
observed the differential expression of 679 protein coding genes and 15 ncRNAs in PBMCs from a 
cohort of patients with symptomatic OA in multiple joints in the hand or at least two joints from hand, 
spine, knee or hip. Differential expression of 22 genes identified out of the 694 were observed to be 
differentially expressed following qPCR validation and also in an independent cohort of OA patients 
[107].  
Attur et al identified 173 differentially expressed genes in PBMCs from patients with OA and also 
showed that symptomatic knee OA patients could be categorised into two subclasses dependent on the 
expression of cytokines in PBMCs. Individuals that exhibited up-regulated expression of cytokines in 
PBMCs, sub-classed as cytokine overexpressors, were found to have higher pain scores and a higher 
risk for symptomatic radiographic knee OA progression. Cytokine gene expression profiling of PBMCs 
may therefore identify a subset of patients with an inflammatory phenotype who may be at risk of rapid 
OA progression [108].  
An in vivo murine model of monosodium iodoacetate-induced OA enabled examination of whole blood 
gene expression profiles with the development of OA, identifying time-dependent differential gene 
expression and therefore potential stage-specific genomic biomarkers of OA progression. Additionally, 
utilising the gene expression dataset from the study conducted by Ramos et al [107], common 
differential gene expression changes in both OA patients and the murine model dataset were examined. 
The expression of TNK2, WDR37 and KCTD2 mRNA were found to be differentially expressed in both 
studies [109]. 
In addition to measurements of RNA as a source from PBMCs as potential OA genomic biomarkers, 
measurements of DNA or DNA characteristics from PBMCs may also function as genomic biomarkers 
of OA. PBMC DNA methylation examination identified differential methylation of 44 CpG sites 
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between PBMC DNA obtained from OA patients with rapid-progressive radiographic knee OA and 
PBMC DNA from patients with non-progressive radiographic knee OA.  Differential DNA methylation 
may therefore serve as a genomic biomarker for predicting rate of OA radiographic progression in 
symptomatic knee OA patients [110].  
Despite the relatively low number of studies conducted to date which examine extracellular genomic 
material in OA, some of the studies identify the same genomic marker in individuals with knee OA. 
The expression of miR-146a was found to be dysregulated in studies of the synovial fluid [67,68], as 
well as plasma [72] and PBMCs [74], indicating that miR-146a may be a favourable extracellular 
genomic biomarker for identifying individuals with knee OA. The observed expression of miR-146a in 
differing body fluids of individuals with knee OA indicates the usage of several body fluids for 
examining the levels of miR-146a in the potential diagnosis of knee OA. The studies outlined 
demonstrate the recent efforts to identify soluble extracellular genomic biomarkers of OA. Larger 
cohorts are required to examine and validate these potential extracellular genomic biomarkers of OA.  
3.4 Liquid biopsies - the potential for genomic biomarkers of OA in diagnostic testing 
Liquid biopsy is a non-invasive tool for analysing different components of biological fluids to make a 
diagnosis without the need of invasive techniques [111]. Components of body fluids such as cfDNA, 
RNA subtypes including mRNA, miRNA and lncRNA, proteins, exosomes, cfDNA characteristics 
including methylation, integrity, mutation and copy number can be measured following liquid biopsy 
[112]. Liquid biopsy provides a non-invasive approach which is associated with decreased morbidity 
and can be performed successively offering temporal disease monitoring [112]. In 2015 liquid biopsy 
was listed as a top ten technology breakthrough by the MIT Technology Review [113]. Liquid biopsies 
are already used in the clinicand some of the diagnostic tests which currently employ liquid biopsies 
for measuring extracellular genomic material are outlined below.  
Exosome Diagnostics produced the first blood-based liquid biopsy cancer diagnostic, ExoDx Lung 
(ALK), which measures exosomal-derived EML4-ALK fusion transcripts from the plasma of patients 
with non-small cell lung cancer [114]. Exosome Diagnostics also produced the first urine-based liquid 
biopsy diagnostic, ExoDx Prostate (IntelliScore), which detects exosomal-derived RNA of ERG, PCA3 
and SPDEF in the urine of men with prostate-specific antigen, to discriminate high grade from low-
grade prostate cancer and benign disease [115]. The AlloMap test, marketed by CareDx, is a non-
invasive blood test to analyse RNA from PBMCs for the expression of 20 genes, to assess the risk of 
moderate/severe acute cellular rejection in cardiac transplant recipients [116]. Recently CareDx has 
brought to market another non-invasive blood test, AlloSure, which measures donor-derived cfDNA to 
determine active rejection of kidney allografts in renal transplant recipients [117]. All of the genomic 
liquid biopsy based diagnostic assays outlined above offer non-invasive screening over previously 
available invasive procedures. Measurement of extracellular genomic material and measurements of 
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characteristics of genomic material from body fluids including synovial fluid and blood provides a 
promising method for the identification of genomic biomarkers of early-onset OA and in monitoring 
OA disease progression. Ultimately liquid biopsies such as synovial fluid and blood sampling could be 
used in the diagnosis and monitoring of OA disease progression in the future. 
4. Extracellular carriers of genomic material as potential indicators of OA disease 
progression 
Stability of extracellular RNA is likely to be attributable to association of RNA with extracellular 
carriers such as exosomes, microvesicles, apoptotic bodies, lipoproteins or protein complexes [39]. EVs 
can be categorised into exosomes, microvesicles and apoptotic bodies and are generated through distinct 
cellular mechanisms. Exosomes refer to EVs that are of endosomal origin. Endosomes constitute part 
of the network which guides cell contents to either lysosomes for lysosomal degradation or the cell 
surface membrane for secretion. Fusion of intracellular multivesicular bodies, which constitute the 
endosomal pathway, with the plasma membrane results in secretion of exosomes into the extracellular 
space [118].  Microvesicles are of plasma membrane origin and are formed through the budding and 
fission of the plasma membrane [118]. Apoptotic bodies are only formed during apoptosis. Cells 
undergoing programmed cell death follow a process of nuclear chromatin condensation, followed by 
membrane blebbing and the dissolution of the cell contents into membrane enclosed vesicles, known as 
apoptotic bodies [118].  
In addition to EVs as carriers of extracellular RNA are lipoproteins and protein complexes. Lipoproteins 
are an assembly of phospholipids, apolipoproteins, cholesterol and a core containing triglycerides and 
cholesterol esters [119]. Human high density lipoproteins (HDLs) have been shown to contain small 
RNAs and have been suggested to function in intercellular communication through transportation of 
miRNA [120]. Extracellular miRNA has also been shown to be associated with argonaute proteins 
[66,121] and miRNA association with argonaute proteins increases miRNA stability [122]. During 
intracellular miRNA mediated mRNA targeting, mature miRNAs complex with argonaute proteins to 
form a ribonucleoprotein complex, the RNA-induced silencing complex (RISC) [123], therefore 
miRNA association with argonaute proteins in the extracellular environment is not unexpected.  
With regards to using extracellular genomic material as potential soluble genomic biomarkers of OA, 
the associated nucleic acid carrier and therefore the pathway of secretion of genomic material from any 
of the affected cells of the joint into extracellular environments may be extremely relevant to identifying 
specific stage-related OA genomic biomarkers. The extent to which intracellular nucleic acids are 
released from cells non-selectively and the extent to which intracellular nucleic acids are pre-
determined and sorted for extracellular secretion in a paracrine manner is unknown [124]. Two 
hypotheses have been proposed for the existence of extracellular miRNA: the existence of selective 
miRNA export systems have been proposed and alternatively the concept that extracellular miRNA are 
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merely by-products of cell activity and cell death [125] and therefore released non-selectively. But it is 
likely that intracellular RNA can be released both selectively and non-selectively.  
Following cell death, tissue-specific RNAs may be released non-selectively, whereby the elevated 
expression of extracellular RNA may reflect the high abundance of RNA that were located in the cells 
of origin. While RNA release may be as a consequence of leakage from damaged cells undergoing 
apoptosis and/or necrosis, RNA release may also have a biological function, in which case RNA may 
be selectively released utilising specific intracellular membrane trafficking pathways. Approximately 
90% of circulating miRNAs have been suggested to be associated with a ribonucleoprotein complex, 
while approximately 10% have been suggested to be vesicle-associated [121]. Turchinovich et al 
proposed that the majority of circulating miRNA that are bound to the ribonucleoprotein Ago2, are 
likely to be by-products of dead cells [66]. In late-stage OA, chondrocyte apoptosis is evidenced by 
hypocellularity and lacunae emptying [98]. If the majority of circulating miRNA that are bound to Ago2 
are likely to be by-products of dead cells [66], measurements of only non-vesicle Ago2-associated 
miRNAs in the extracellular fluids of OA patients could serve as potential biomarkers for apoptosis of 
specific joint cells and therefore give a potential indication of disease progression.  
5. Future challenges for genomic biomarkers of osteoarthritis 
A biomarker can be defined as anything which enables an observation of medical state to be made from 
outside of the patient, which can be measured both accurately and reproducibly [126], a defined 
characteristic which when measured gives an indication of normal biological processes, pathogenic 
processes and responses to an intervention or exposure. Recent efforts have identified that extracellular 
nucleic acids, both carrier-associated and non-carrier associated, including miRNA, lncRNA, snoRNA 
and DNA have been identified to exhibit differential expression in extracellular environments in OA 
and could therefore serve as appropriate soluble genomic biomarkers of OA. Future studies to examine 
these identified potential genomic biomarkers for reproducibility in larger validation cohorts are 
required. 
While efforts are required to advance the identification of biomarkers in OA, efforts will also be 
required to identify individuals at-risk of developing OA through the implementation of screening 
programmes as routine procedure in clinical practice. A limitation of soluble biomarker discovery is the 
asymptomatic nature of pre-OA which limits the point in time at which an individual can be directed 
for examination. Chu et al suggest that longitudinal studies of human joint-injured cohorts provide the 
opportunity to characterise and define pre-OA because these populations have joint pathologies 
whereby OA is likely to develop [127]. With regards to identifying a genomic biomarker for pre-OA, 
one idea could be the implementation of a longitudinal study with use of extracellular nucleic acid 
profiling in individuals who have been subject to a joint injury. For example, as discussed previously, 
Zhang et al identified extracellular ncRNAs one year after ACL injury and examined the correlation of 
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serum-derived ncRNA concentration with extent of cartilage damage [86]. Studies need to focus on 
identification and stratification of at-risk asymptomatic individuals without radiographic OA for 
longitudinal studies with cohorts which are likely to have a predisposition of developing a specific 
phenotype of OA. 
An injury driven phenotype is just one subtype of OA. Given the complex nature of OA, it is likely that 
no single biomarker will be appropriate for all phenotypes of OA. In addition to the differing phenotypes 
of OA is also the anatomical location of OA. At present, OA can be categorised into primary (idiopathic) 
OA and secondary OA. Secondary OA is associated with causes such as congenital or developmental 
deformities, preceded joint trauma or surgery, metabolic or endocrine disorders. Primary OA is most 
common and occurs in joints with no prior damage and can be further categorised into generalised and 
localised OA. Generalised OA (polyarticular) occurs in multiple joints, whereas localised OA is 
confined to 1 or 2 joints [128]. Most extracellular genomic material studies of OA to date, discussed in 
this review, examine the expression of extracellular genomic material in patients with only knee OA. 
While knee OA genomic biomarker discovery will be more accelerated, genomic biomarker discovery 
of OA of the hip, OA of the joints of the hand and generalised OA may lag behind. Future priorities 
need to categorise OA into disease subtypes according to potential underlying phenotype in addition to 
anatomical location/s, with the view to identify soluble biomarkers that are inherent to a specific type 
of OA.  
Of the extracellular genomic material studies of OA to date, discussed in this review, only one study 
isolated RNA from the exosome fraction of synovial fluid [68], all of the other studies isolated total 
RNA from either synovial fluid, serum or plasma. The method of RNA isolation from extracellular fluid 
is likely to be relevant to identifying genomic biomarkers, with potential differences in extracellular 
RNA expression dependent on the isolation procedure utilised. However, at present, limitations exist in 
the lack of discrimination between extracellular nucleic acid carriers. Isolation of a pure EV fraction 
from extracellular fluids is challenging because non-vesicular entities such as lipoproteins and proteins 
complexes are not separated from EVs by isolation protocols such as centrifugation [129] and Ago-2 
has been identified inside exosomes [130]. Furthermore there is much overlap in the sizes of specific 
EVs, with exosomes measuring between 40-200 nm in diameter, microvesicles measuring between 50-
1000 nm in diameter and apoptotic bodies measuring between 500-2000 nm in diameter [131] which 
makes separation and isolation of subtypes of EVs difficult. Lack of defined nucleic acid carrier 
isolation and characterisation techniques may limit efforts to examine selective and non-selective 
release of nucleic acid from chondrocytes and synoviocytes. What is critical in extracellular genomic 
biomarker research is the necessity to appropriately document extracellular sources of genomic material 
with the implementation of strict guidelines for categorising nucleic acid carriers.  
Personalised medicine is a rapidly growing field which is informed by the underlying molecular 
mechanisms of a disease in order of optimising preventative health care strategies, directing medical 
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care towards assessing disease risk and prevention [132]. A companion diagnostic is any in vitro 
diagnostic device or imaging tool that provides essential information for the safe and effective use of a 
corresponding therapeutic product [133]. The importance of identifying a soluble biomarker/s of OA, 
is the potential that biomarker may have in being utilised as a liquid biopsy-based companion diagnostic 
for screening participants in the detection of OA for inclusion in clinical trials, in the development of 
much needed DMOADSs [134].  
Expert commentary 
The definitive objective of OA biomarker research is to identify OA prior to radiographic evidence of 
OA. For the future, an annual biological test is necessary to detect pre- or early-onset OA while OA is 
either still curable or at a less advanced stage of the disease progress at which point potential DMOADs 
will forestall the progression of the disease. All cells release nucleic acids into the extracellular 
environment and by association with RNA-binding proteins or lipoproteins or carriage within EVs, 
nucleic acids are thought to be protected from degradation. Biological fluids are more accessible than 
tissues and provide an appealing and non-invasive source for the measurement of extracellular genomic 
material. Future OA research prerequisites include identifying stable and reproducible extracellular 
genomic biomarkers of pre- and early-onset OA and extracellular genomic biomarkers which can 
discriminate between stages of OA progression, which may lead to the creation of OA specific non-
invasive liquid biopsy diagnostics. 
Documented to date, genomic material that has been observed in extracellular environments in OA, 
such as synovial fluid and plasma and/or serum includes cfDNA, miRNA, lncRNA and snoRNA. A 
diverse composition of RNA subsets have been identified in EVs including tRNA fragments, rRNA, 
vault RNA, circRNA, piRNA, Y RNA (Table 2) [36] and cell-free telomeric repeats-containing RNA 
(cfTERRA) [135], all of which could be present and exhibit differential expression in the extracellular 
fluids of OA patients. Future studies to investigate the presence of RNA subsets in OA may reveal 
additional RNA candidates that could serve as genomic biomarkers of OA. Other epigenomic alterations 
such as histone modifications [136], enabling measurements of histone methylation, acetylation, 
phosphorylation and ubiquitination in PBMCs of OA patients, may also function as potential genomic 
biomarkers. Extracellular fluid analysis holds much promise for the identification of genomic 
biomarkers of OA, but a combination of techniques inclusive of genomics, proteomics, and 
metabolomics used together, is likely to identify a more powerful biomarker panel capable of detecting 
OA early.  
Recently liquid biopsy has gained much attention in the cancer sciences field, but this novel technique 
set to revolutionise diagnostics has far reaching implications not just in the field of oncology but in 
other diseases too. As advances are made in OA research, in the future not only could liquid biopsy be 
a useful method for OA disease progression monitoring, but also in the initial screening of individuals 
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for OA detection and also in the stratification of individuals according to OA phenotype, made possible 
by anticipated discovery of reliable informative single nucleotide polymorphisms.  
Beyond the scope of this review is the potential link that mechanisms of selective and non-selective 
release of genomic material from cells of the OA joint may have in OA disease pathogenesis. In the 
search for a suitable extracellular biomarker of OA opens up questions about the potential role that 
conventional and unconventional secretory pathways may have in secreting genomic material to the 
extracellular environment. In addition to exploring intracellular trafficking pathways including 
exocytosis, microvesical shedding and exosome secretion, exploring exosome secretion as a result of 
plasma membrane fusion with secretory lysosomes and amphisomes in addition to multivesicular bodies 
may reveal links to autophagy and an indication of underlying cellular health in OA. The extent of 
which specific nucleic acid carrier subtypes are released from cells of the joint may have indications 
for cellular homeostatic status. The type of extracellular carrier associated with extracellular genomic 
material and the mode of secretion may indicate how cells of the joint function in health and disease, 
revealing roles for genomic material in cell-cell communication and the potential to reveal more about 
the underlying pathophysiology of OA. A more profound understanding of the mechanisms of release 
of genomic material into the extracellular environment in the cells of the joint is required.  
Five-year view 
At present, the field of extracellular genomic biomarker research is primitive and in the next few years, 
extracellular genomic biomarker research is anticipated to grow, with the identification of novel subsets 
of extracellular RNA isolated from the extracellular fluids of OA patients. In vitro cell and explant 
culture systems will likely be routinely used to validate and further explore identified extracellular 
genomic biomarkers. It is expected that there will be a focus on EV-derived genomic material and it is 
anticipated that technologies utilised to extract extracellular genomic material will continue to grow 
and move towards isolation of pure fractions of extracellular nucleic acid carrier subtypes, such as 
subsets of EVs. As a greater understanding regarding extracellular genomic material develops, 
pathways of intracellular cell trafficking of genomic material to the plasma membrane will also develop 
and may reveal more about the underlying dysregulated mechanisms which may be involved in the 
pathophysiology of OA. In addition to expected identification of extracellular metabolomic and 
proteomic biomarkers of OA, with the identification of differential measurements of extracellular 
genomic material in OA which could function as genomic biomarkers of OA, the number of human 
biomarker studies to assess panels of a combination of biomarkers from different body fluids is expected 
to increase. It is anticipated that in the event of successful identification of soluble biomarkers for 
diagnosing OA, soluble biomarkers will be in the first instance adjunct to and then definitively in place 
of radiographic measurements as the regulatory endpoint in DMOAD development. 
Key Issues 
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 Osteoarthritis (OA) is a chronic and debilitating disease which affects approximately a third of 
the UK’s population that are aged over 45 years and a diagnosis of OA is currently based on 
radiographic findings at which point structural changes are observed in the affected joint. 
 While recent efforts have looked to address the notion that OA is indeed a serious disease, much 
more needs to be done to drive forwards biomarker discovery and the development of 
DMOADs. 
 The OA disease process is estimated to begin 20 years prior to detection by radiographic joint 
space narrowing with the likelihood that molecular indicators exist at the cellular level only, a 
stage that can be defined as pre-OA. 
 No soluble biomarkers exist which can detect OA or determine the progression of the disease. 
Asymptomatic OA is a common phenomenon. Identification of suitable soluble biomarkers 
would potentially help identify asymptomatic individuals and also pre-OA in routine screening 
and to assess disease progression. 
 Examination of extracellular body fluids for biomarkers offers a non-invasive method for 
assessing disease state. Body fluids including synovial fluid and blood which can be analysed 
for measurements of extracellular genomic material have the potential to serve as liquid 
biopsies in the diagnosis of OA. 
 Several recent studies observe the differential expression of subsets of ncRNA in extracellular 
fluids including synovial fluid, plasma and serum of OA patients, indicating the potential use 
of ncRNAs such as miRNAs, lncRNAs and snoRNAs as diagnostic and prognostic biomarkers 
for OA. 
 Studies of PBMCs in OA has observed the differential expression of miRNA, mRNA and 
differential measurements of DNA methylation, suggesting that isolation of PBMCs could 
provide a source of genomic material as diagnostic and prognostic biomarkers for assessing 
OA disease. 
 RNA exists in extracellular fluids by association with a carrier, which protects the RNA from 
degradation. Carriers of genomic material may include lipoproteins, protein carriers and EVs 
such as exosomes, microvesicles and apoptotic bodies. 
 The type of carrier that genomic material may be associated with may give indications about 
how intracellular genomic material is secreted or released to the extracellular environment. 
How genetic material is secreted or released from cells of the joint including chondrocytes and 
synoviocytes, with regards to specific intracellular trafficking pathways, may give an indication 
to the underlying health of the cell of origin and reveal more about OA pathophysiology. 
 Drug and biomarker development are interdependent. The development of DMOADs requires 
a biomarker which can detect OA and predict OA disease progression. In the future, 
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identification of OA before radiographic evidence of OA, using extracellular-derived soluble 
biomarkers, could see the use of effective DMOADs forestalling the onset of OA. 
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Figure 1. Extracellular carrier-associated and extracellular carrier-free genomic material from body fluids with 
the potential to serve as genomic biomarkers in OA. To date extracellular genomic material has been identified in 
synovial fluid, plasma and serum. Peripheral blood mononuclear cells (PBMCs) have been isolated from blood 
and identified to exhibit differential expression of mRNA and miRNA in OA patients. PBMCs include monocytes, 
lymphocytes, dendritic cells and natural killer cells. Extracellular genomic material found in synovial fluid, 
plasma and/or serum may be contained inside extracellular vesicles including apoptotic bodies, microvesicles and 
exosomes or associated with a protein complex such as Argonaute2 or high density lipoproteins (HDLs) or not 
associated with a carrier, such as cell-free DNA (cfDNA). TMJ –Temporomandibular joint. ↑ – Up-regulated 
expression or concentration. ↓ – Down-regulated expression or concentration. Documented studies have 
observed the differential expression/concentration/level of specific extracellular genomic material between 
rheumatoid arthritis patients (RA) and patients with knee OA, between non-OA patients and patients with mild 
and severe knee OA, between non-OA patients and mild OA patients, between non-OA patients and patients with 
TMJ OA. 
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Figure 2. DNA encodes both protein coding genes and non-coding DNA. Only a small proportion of DNA is 
protein coding DNA, in which the DNA is transcribed to mRNA which in turn is translated to protein. Non-coding 
DNA includes non-functional DNA which has no known function and functional DNA which includes DNA 
sequences which have known functions and include for example: cis-regulatory elements, scaffold/matrix 
(S/MAR) attachment regions, introns, telomeres and DNA which encodes genes for non-coding RNA. Functional 
non-coding RNA encompasses RNAs which are not translated into protein but have functional roles and include 
miRNAs, lncRNAs, snoRNAs, snRNAs, piRNAs, vtRNAs, Y RNA, circRNAs, tRFs, rRNAs and tRNAs. Many 
ncRNAs have housekeeping and regulatory roles. SnRNAs for example have roles in processing pre-mRNA 
during splicing and tRNA is fundamental to protein biosynthesis in ribosomes. MiRNAs have roles in regulating 
gene expression, via post-transcriptional regulation of mRNA, generally via binding to the 3ʹUTR of target 
mRNA. One function of circRNA is the regulation of gene expression through the targeting of miRNA, enabling 
derepression of miRNA targeted mRNA. 
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MicroRNA 
Human 
synovial Fluid 
Knee 
Total RNA 
from 
synovial 
fluid. 
Differential expression of 
synovial fluid miRNAs 
between radiographic 
early-stage and late-stage 
OA (assessed by KL 
grading). 
14 miRNAs 
differentially 
expressed in 
miRNA PCR 
array. 
miR-23a-3p ↑ 
miR-24-3p ↑ 
miR-27a-3p ↑ 
miR-27b-3p ↑ 
miR-29c-3p ↑ 
miR-34a-5p ↑ 
miR-186-5p ↑ 
miR-378a-5p ↑ 
(Significantly up-
regulated in late-stage 
OA compared to early-
stage OA). 
Prognostic 
biomarkers 
of knee OA 
disease 
progression. 
[69] 
Conditioned 
media from 
human 
synovial 
explant culture 
Synovial 
explants 
from the 
knee joint 
Total RNA 
from cell 
culture 
supernatant. 
Differential expression of 
cell culture supernatant 
miRNAs in response to IL-
1β stimulation. 
- 
miR-23a-3p ↑ 
miR-27b-3p ↑ 
(Significantly 
upregulated with IL-1β 
stimulation). 
Diagnostic 
biomarkers 
of 
inflammator
y knee OA. 
[69] 
Human 
synovial Fluid 
Knee 
Total RNA 
from 
synovial 
fluid. 
Differential concentration 
of synovial fluid miRNAs 
between patients with OA 
and RA 
(assessed by 1986 
classification of knee OA 
in diagnostic criteria of the 
American Rheumatism 
Association [137]). 
- 
miR-16 ↓ 
miR-146a ↓ 
miR-155 ↓ 
miR-223 ↓ 
(Lower concentration in 
OA compared to RA) 
Diagnostic 
biomarkers 
of knee OA 
and RA. 
Assessment 
of 
concentratio
n required to 
differentiate 
knee OA 
from RA - 
lower 
concentratio
n in OA than 
RA.  
[67] 
Human 
plasma 
Knee 
Total RNA 
from plasma 
Differential expression of 
plasma miRNAs between 
patients with OA, RA and 
healthy controls (HC) 
(assessed by 1986 
classification of knee OA 
in diagnostic criteria of the 
American Rheumatism 
Association [137]). 
- 
miR-16 ↓ 
miR-132 ↓ 
(Significantly lower 
concentration in OA 
compared to HC) 
miR-132 -
diagnostic 
biomarker of 
knee OA and 
RA, but not 
inherent to 
knee OA as 
no 
differences 
observed 
when OA 
compared to 
RA. 
miR-16 – 
diagnostic 
biomarker of 
knee OA. 
[67] 
Human 
synovial Fluid 
Knee 
Total 
miRNA 
from 
Differential expression of 
synovial fluid-derived 
extracellular vesicle-
derived miRNAs between 
114 miRNAs 
differentially 
expressed in 
males  
miR-26a-5p ↓ 
miR-146a-5p ↓ 
miR-6821-3p ↓ 
Diagnostic 
biomarkers 
of knee OA 
[68] 
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extracellular 
vesicles  
patients with OA and 
without OA and between 
male and female. 
144 miRNAs 
differentially 
expressed in 
females  
in 
miRNA array 
miR-504-3p ↑  
(Only miRNA 
to be up-
regulated in 
both male and 
female). 
(Significantly down-
regulated expression in 
female OA compared to 
female non-OA). 
in females 
only. 
Human 
synovial fluid 
Knee 
Total small 
RNAs from 
synovial 
fluid 
supernatant. 
To examine the expression 
of synovial fluid miR-140 
between non-OA and 
radiographic mild, 
moderate and severe OA 
 (assessed by KL grading). 
- 
miR-140 ↓ 
(with increasing 
radiographic severity of 
OA). 
Prognostic 
biomarker of 
knee OA 
disease 
progression. 
[70] 
Human serum 
Knee and/or 
hip 
Total RNA 
from serum. 
Differential expression of 
serum miRNAs between 
patients with OA-related 
knee or hip arthroplasty 
compared to individuals 
without arthroplasty. 
12 miRNAs 
differentially 
expressed in 
miRNA array. 
let-7e ↓ 
(with increasing number 
of hip/knee joint 
replacement surgeries). 
Diagnostic 
biomarker of 
knee and/or 
hip OA and 
likelihood 
for need of 
knee and/or 
hip 
arthroplasty. 
[71] 
Human 
plasma 
Knee 
Total RNA 
from plasma. 
Differential expression of 
plasma miRNAs between 
patients with radiographic 
knee OA and patients 
without clinical diagnosis 
of OA 
(assessed by KL grading). 
12 miRNAs 
differentially 
expressed in 
miRNA array. 
miR-29c ↑ 
miR-93 ↑ 
miR-126 ↑ 
miR-184 ↑ 
miR-186 ↑ 
miR-195 ↑ 
miR-345 ↑ 
miR-885-5p ↑ 
miR-16 ↑ 
miR-146a ↑ 
(Up-regulated expression 
in OA compared to non-
OA). 
Diagnostic 
biomarkers 
of knee OA. 
[72] 
Human 
plasma 
Knee 
Total RNA 
from plasma. 
Differential expression of 
plasma miRNAs between 
patients with knee OA and 
healthy controls (HC) 
(assessed by 1986 
classification of knee OA 
in diagnostic criteria of the 
American Rheumatism 
Association [137]). 
70 miRNAs 
differentially 
expressed in 
miRNA array. 
miR-19b-3p↑ 
miR-92a-3p ↑ 
miR-122-5p ↑ 
miR-486-5p ↑ 
(Up-regulated expression 
in OA compared to HC). 
Diagnostic 
biomarkers 
of knee OA. 
[73] 
Human blood 
- PBMCs 
Knee 
Total RNA 
from 
PBMCs. 
Differential expression of 
PBMC-derived miRNA 
between patients with RA, 
knee OA and healthy 
controls (HC) (assessed by 
1986 classification of knee 
OA in diagnostic criteria of 
the American Rheumatism 
Association [137]). 
 
 
- 
miR-146a↑ 
miR-155 ↑ 
miR-181a ↑ 
miR-223 ↑ 
(Significantly up-
regulated expression in 
both RA and OA 
compared to HC). 
 
miR-146a ↓ 
miR-155 ↓ 
Diagnostic 
biomarkers 
of knee OA 
and RA. 
Assessment 
of 
expression 
required to 
differentiate 
OA from RA 
– lower 
[74] 
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Differential expression of 
PBMC-derived miRNA 
between radiographic 
stages of OA (assessed by 
KL grading). 
miR-223 ↓ 
(Significantly up-
regulated expression in 
RA when compared to 
OA). 
 
miR-146a ↑ in early OA 
miR-223 ↑ in early OA 
miR-155 ↓ in early OA 
expression 
in OA than 
RA. 
 
 
miR-146a 
and miR-223 
biomarkers 
of early OA 
miR-155 
biomarker of 
late-stage 
OA. 
lncRNA 
Human 
synovial fluid 
Temporoma
ndibular 
joint (TMJ) 
Total RNA 
from 
synovial 
fluid. 
Differential expression of 
synovial fluid lncRNAs 
between patients with 
clinical signs and 
symptoms of OA and 
patients without (assessed 
by research diagnostic 
criteria for TMJ disorders).  
- 
HOTAIR ↑ 
(Significantly up-
regulated in OA 
compared to normal 
controls). 
Diagnostic 
biomarker of 
TMJ OA.  
[79] 
snoRNA 
Human serum 
Anterior 
cruciate 
ligament 
(ACL) – 
knee. 
Total RNA 
from serum. 
Differential concentration 
of serum snoRNAs 
between patients one year 
post ACL injury with 
cartilage damage (assessed 
by MRI analysis using 
Whole Organ Magnetic 
Resonance Knee Scoring 
(WORMS)) and in healthy 
donors. 
& 
Between patients one year 
post ACL injury 
developing cartilage 
damage and in patients one 
year post ACL injury 
without evidence of 
cartilage damage (assessed 
by MRI analysis using 
WORMS). 
- 
U48 ↑ 
(Significantly higher 
levels in patients with 
ACL injury with 
cartilage damage 
compared to healthy 
donors). 
 
U38 ↑ 
(Significantly higher 
levels in patients with 
ACL injury with 
cartilage damage 
compared to healthy 
donors) 
& 
Significantly higher 
levels in patients with 
greater cartilage damage 
compared to patients 
with minor cartilage 
damage). 
 
Diagnostic 
biomarkers 
of cartilage 
damage. 
 
U38 can 
differentiate 
between 
minor and 
greater 
cartilage 
damage 
induced by 
ACL injury 
– U38 
biomarker of 
early ACL 
induced 
damage. 
[86] 
Mice serum 
Not stated in 
study 
Total RNA 
from serum. 
Differential expression of 
serum snoRNAs between 
old sham mice and mice 
with experimentally 
induced destabilisation of 
the medial meniscus 
(DMM). 
18 snoRNAs 
differentially 
expressed 
snoRNASeq. 
SNORD116 ↑ 
SNORA64 ↑ 
U3 ↑ 
(Significantly up-
regulated in 
experimentally induced 
OA compared to control 
sham mice). 
 
SNORD46 ↓ 
(Significantly down-
regulated in 
experimentally induced 
OA compared to control 
sham mice). 
Diagnostic 
biomarkers 
of OA. 
[87] 
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Horse serum 
Not stated in 
study 
Serum 
Differential expression of 
SNORD116 between 
equine OA and normal 
serum. 
- 
SNORD116 ↑ 
(Significantly up-
regulated in OA 
compared to non-OA). 
Diagnostic 
biomarker of 
OA. 
[87] 
DNA 
Human serum  
Not stated in 
study 
DNA from 
serum 
Differential DNA levels in 
patients with RA compared 
to patients with OA. 
- 
DNA level ↓ 
(Significant increase in 
concentration in RA 
compared to OA). 
Differentiate 
between OA 
and RA. 
[96] 
Human 
synovial fluid 
Not stated in 
study 
DNA from 
synovial 
fluid 
Differential DNA levels in 
patients with RA compared 
to patients with OA. 
- 
DNA level ↓ 
(Significant increase in 
concentration in RA 
compared to OA). 
Differentiate 
between OA 
and RA. 
[96] 
Human 
plasma 
Not stated in 
study 
cfDNA from 
plasma 
Differential concentration 
of circulating cfDNA in 
patients with RA compared 
to patient with OA. 
- 
cfDNA level ↓ 
(Significant increase in 
concentration in RA 
compared to OA). 
Differentiate 
between OA 
and RA. 
[97] 
PBMCs 
Human blood Knee 
Total RNA 
from cellular 
fraction of 
blood. 
Differential gene 
expression of total cellular 
blood between patients 
with mild OA and control 
subjects (assessed by 
arthroscopic scoring 
method [138]). 
3,543 
differentially 
expressed 
genes in 
cDNA 
microarray. 
HSPCA mRNA ↓ 
IKBKAP mRNA ↓ 
IL13RA1 mRNA ↓ 
LAMC1 mRNA ↓ 
TNFAIP6 mRNA ↓ 
PF4 mRNA ↓ 
(Significantly down-
regulated in mild knee 
OA compared to 
controls). 
Diagnostic 
biomarkers 
of mild knee 
OA. 
[106] 
Human blood Knee 
Total RNA 
from 
PBMCs. 
Correlation of OA patients 
which identified as having 
up-regulated cytokine 
expression (from blood-
derived PBMCs RNA) 
compared to OA patients 
identified as having low 
cytokine expression, and 
OA radiographic 
progression (assessed by 
- 
IL-1β mRNA ↑ 
TNFα mRNA ↑ 
IL-6 mRNA ↑ 
IL-8 mRNA ↑ 
COX-2 mRNA ↑ 
(Significant up-
regulation in 
inflammatory OA 
subclass). 
Biomarkers 
of 
inflammator
y knee OA 
with 
increased 
risk of rapid 
radiographic 
progression. 
[108] 
Human blood 
Primary OA 
– at multiple 
joint sites in 
the hand, or 
at least two 
joints from 
hand, spine, 
knee or hip. 
Total RNA 
from 
PBMCs. 
Differential gene 
expression of blood-
derived PBMCs between 
OA patients and non-OA 
control subjects (assessed 
by definition of OA 
diagnosis by the American 
College of Rheumatology 
[137]).  
679 genes and 
15 ncRNAs 
differentially 
expressed in 
microarray. 
GPR18 mRNA ↑ 
ZNF564 mRNA ↑ 
XNF20 mRNA ↑ 
RIPK1 mRNA ↑ 
ADRB2 mRNA ↑ 
PELO mRNA ↑ 
SIAH1 mRNA ↑ 
SLA mRNA ↑ 
PLEKHF1 mRNA ↑ 
CASP3 mRNA ↑ 
RABEP1 mRNA  ↑ 
FADD mRNA ↑ 
CLK1 mRNA  ↑ 
ESF2 mRNA ↑ 
(Significant up-
regulation in OA 
compared to non-OA). 
- 
ATF4 mRNA ↓ 
SFRS5 mRNA ↓ 
CDKN2D mRNA ↓ 
PPP1R15A mRNA ↓ 
Diagnostic 
biomarkers 
of OA. 
[107] 
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Table 1. Extracellular carrier-associated and extracellular carrier-free genomic material with the 
potential to serve as genomic biomarkers in OA. ↑ - Up-regulated expression/concentration/level in OA. 
↓ - Down-regulated expression/concentration/level in OA. 
 
 
OSM mRNA  ↓ 
GSTM2 mRNA ↓ 
ERG1 mRNA ↓ 
IL8 mRNA ↓ 
(Significant down-
regulation in OA 
compared to non-OA). 
Rat blood 
Monosodiu
m 
iodoacetate 
(MIA)-
induced OA 
of the knee 
joint. 
Total RNA 
from whole 
blood. 
Time course gene 
expression of MIA induced 
OA and comparison of 
microarray dataset to 
microarray dataset 
obtained from the human 
GARP study [107]. 
72 genes 
differentially 
expressed 
during 
development 
of MIA –
induced OA in 
microarray. 
Tnk2 mRNA 
Wdr37 mRNA 
Kctd2 mRNA 
(Differentially expressed 
in both rat model and 
OA patients). 
Diagnostic 
biomarkers 
of OA. 
[109] 
Human blood Knee 
DNA from 
PBMCs. 
Differential methylation of 
CpG sites of blood-derived 
PBMC DNA between 
patients with rapid 
progressive OA and 
patients with non-
progressive OA (assessed 
by radiographic joint space 
loss at follow-up and need 
for arthroplasty). 
- 
44 CpG sites 
(Differentially 
methylated between 
rapid and non-
progressive OA). 
Methylation 
status as a 
biomarker 
for 
predicting 
future 
radiographic 
progression 
of knee OA. 
[110] 
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Functional 
non-coding 
RNA (ncRNA) 
Definition and function 
MicroRNA 
(miRNA) 
MiRNA are single stranded ncRNA of approximately 22 nucleotides in length. MiRNA function by binding to locations 
within mRNA, typically within the 3’UTR, following RNA transcription [47]. The seed sequence of the miRNA is 
responsible for miRNA-mRNA binding and is a sequence of at least 6 nucleotides positioned at the 5’ end of the 
miRNA and base pairs with perfect complementarity to a target sequence within the mRNA 3’UTR [139]. The binding 
of miRNA to mRNA, in the cytoplasm, prevents mRNA translation in the synthesis of protein. MiRNA is therefore 
capable of down-regulating protein expression through effective mRNA targeting [48]. 
Long non-
coding RNA 
(lncRNA) 
The definition of lncRNAs is limited to ncRNAs of more than 200 nucleotides in length which lack protein coding 
capability [75]. LncRNAs have been classified according to molecular mechanism and can be subtyped as having 
signalling, decoy, guide, scaffold and enhancer roles [77]. LncRNAs can also be subtyped according to their position 
and direction of transcription relative to other genes and can be classified into subtypes including intergenic, intronic, 
antisense, overlapping, processed and bidirectional lncRNAs [78]. For example lncRNAs include some cis-natural 
antisense transcripts (NATs), antisense ncRNA of sequence complementarity to coding RNA from the same genomic 
locus, which function to regulate expression of sense transcripts. LncRNAs include some trans-NATs, antisense 
ncRNA of sequence complementarity to coding RNA from a distal genomic locus, which functions to regulate sense 
transcripts. LncRNAs include long intergenic ncRNA (lincRNA) which are encoded in intergenic regions of DNA, 
sense overlapping lncRNAs which are transcribed from the same strand of DNA as another transcript, sense intronic 
lncRNAs which are encoded in introns of coding genes and processed lncRNAs which can be spliced and/or 
polyadenylated [76]. Different lncRNAs are involved in different biological functions in both the nucleus and 
cytoplasm. LncRNAs have been observed to have roles in chromatin modification through recruitment of chromatin 
modifying complexes. LncRNAs have been observed to have roles in transcriptional regulation, for example by 
functioning as decoys for transcription factors, functioning as transcription factor co-regulators and by inhibiting 
formation of transcription machinery. LncRNAs have also been observed to have roles in post-transcriptional 
regulation, for example by interacting with splicing factors and hindering spliceosome formation, by increasing or 
decreasing mRNA stability, by masking miRNA binding sites in mRNA 3’UTR and by acting as miRNA sponges to 
prevent miRNA binding to target mRNA [140]. 
Small nuclear 
RNA (snRNA) 
SnRNA, located in the nucleus, function in the process of splicing, aiding in the processing of pre-mRNA to mature 
mRNA in the removal of introns. SnRNAs associate with small nuclear ribonucleoproteins to form the spliceosome. 
The snRNAs function as ribozymes, mediating base pairing with RNA [141]. Spliceosomal snRNAs include U1, U2, 
U4, U5, and U6 have roles in substrate recognition at splice sites, in lariat formation and splicing catalysis [142]. 
Small nucleolar 
RNA (snoRNA) 
SnoRNAs, a sub-class of snRNA located in the nucleus, are involved with post-transcriptional modification by means 
of methylation or pseudouridylation of non-coding RNA including snRNA, rRNA and tRNA. SnoRNAs are divided 
into two classes, SNORDs and SNORAs, dependent on their structural features and sequence [84]. SNORDs are box 
C/D snoRNAs, are approximately 70-120 nucleotides in length and contain two conserved elements: box C 
(PuUGAUGA) located at the 5’- termini and box D (CUGA) located at the 3’- termini. The sequence elements form 
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stem-bulge-stem folding domains which serve as scaffolds for small nucleolar ribonucleoprotein (snoRNP) assembly. 
The Box C/D snoRNA: snoRNP complex catalyses site specific 2’-O-methylation in target RNA [85]. SNORAs are 
box H/ACA snoRNAs are hairpin-hinge-hairpin-tail structures which contain two conserved elements: box H 
(ANANNA) (N is any nucleotide) and box ACA which is a trinucleotide located 3 nucleotides upstream of the 3’- 
terminus. Box H/ACA snoRNAs associate with snoRNPs which catalyse pseudouridylation in target RNA [85]. Cajal-
body-specific RNAs (scaRNAs) are snoRNAs which commonly contain features of both SNORDs and SNORAs and 
also contain an element called the Cajal body box (CAB box). ScaRNAs are located within Cajal bodies and are 
involved with methylation and pseudouridylation of spliceosomal snRNAs [143].  In addition to their role in the 
modification of other ncRNA, snoRNAs can be further processed to generate smaller fragments known as sno-derived 
RNAs (sdRNAs) which possess miRNA-like features [144], [145].  
Transfer RNA 
(tRNA) 
tRNAs, approximately 76 nucleotides in length, are fundamental to the process of protein biosynthesis and participate 
in translating codons of mRNA into corresponding amino acids and for each canonical amino acid a subset of tRNA 
species exist [146]. tRNAs are aminoacylated by aminoacyl-tRNA synthetase and the resultant aminoacyl-tRNAs are 
directed to the ribosome where the tRNA locates to the tRNA binding site. At the tRNA binding site the anticodon 
sequence in the tRNA base-pairs with the codon sequence in the mRNA, which specifies the aminoacylated attached 
amino acid [147]. tRNAs exhibit a cloverleaf-shaped secondary structure which ultimately folds into an L-shaped 
tertiary structure which is fundamental to its role [146].  
Transfer RNA-
derived RNA 
fragments 
(tRFs) 
tRFs are processed from pre-tRNA and mature t-RNA, generated from all parts of the tRNA molecule. tRFs were 
assumed to be inert but have recently been observed to be produced to function in processes including stress response, 
translation inhibition and proliferation  [148].  
Ribosomal RNA 
(rRNA) 
rRNA ranges in size from 120 to 5000 nucleotides and are a key component of ribosomes and therefore play a 
fundamental role in protein biosynthesis. Ribosomes are composed of proteins and several different rRNA molecules 
which are organised into a small subunit and a large subunit [147]. The ribosome comprises of rRNA which possesses 
ribozymal activity. The small subunit of the ribosome mediates the interactions between the tRNA anticodons and 
mRNA codons and the large subunit catalyses the formation of the peptide bond, with rRNA 28S being responsible for 
peptidyl transferase activity of the ribosome [149]. 
Circular RNA 
(circRNA) 
CircRNA is non-linear, with the 3’ and 5’ ends joined together resulting in a circular structure, generated from the 
backsplicing of introns and/or exons. CircRNA has been proposed to be stable as a result of its structure which prevents 
degradation by RNA exonucleases and therefore is abundant in the cytoplasm. CircRNAs have been suggested to 
function as miRNA sponges and therefore may play a role in gene expression regulation by regulating miRNA 
expression [150]. Additional potential roles for circRNA include interacting with RNA binding proteins, modulating 
mRNA stability and regulating gene transcription [151]. 
Piwi-interacting 
RNA (piRNA) 
piRNAs are 24-31 nucleotides in length and interact with PIWI proteins. PIWI proteins and piRNA constitute piRNA-
induced silencing complexes which function to repress transposons [152]. piRNAs are enriched in germline tissues, 
and through the silencing of mobile elements, are thought to prevent accumulation of genome changes [153]. 
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Table 2. Definitions of functional ncRNAs. 
 
Vault RNA 
(vtRNA) 
vtRNAs are approximately 80 to 150 nucleotides in length and are associated with vault particles. Vault particles are 
large cytoplasmic ribonucleoproteins which may have roles in intracellular nucleocytoplasmic transport [154], 
intracellular detoxification, apoptosis resistance, signalling, DNA damage repair, innate immune response and 
formation of the nuclear pore complex [155]. 
Y RNA 
 Y RNAs vary in length between approximately 83 and 112 nucleotides and are folded into conserved stem-loop-
structures. Functions for Y RNA have been proposed and include cell stress response and proliferation regulation, 
DNA replication and small RNA quality control. Y RNA are associated with different core protein s, for example 
the association of Y RNA with Ro60 [156] 
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